Drug Discovery 기술 시장 : 제품별, 기술별, 프로세스별, 치료 분야별 - 세계 예측(-2030년)

The drug discovery technologies market is expected to reach USD 51.51 billion in 2030 from USD 30.58 billion in 2025, at a CAGR of 11.0% during the forecast period. The market is driven by the increasing adoption of advanced screening platforms and the shift toward 3D cell cultures, organoids, and organ-on-a-chip models.

These technologies improve disease relevance, enhance predictive accuracy, and support more efficient and reliable drug discovery processes. Furthermore, the shift towards targeted and precision therapies further boosts demand. However, high technology costs, complex workflows, and the need for skilled professionals continue to limit market growth.

The in-silico/AI-based drug discovery segment is expected to grow at the highest CAGR during the forecast period.

The in silico/AI-based drug discovery technology segment is growing at the highest CAGR in the drug discovery technologies market due to its ability to shorten discovery timelines, reduce costs, and improve success rates. These technologies use computational modeling, machine learning, and data analytics to rapidly identify and optimize drug candidates. By analyzing large biological and chemical datasets, AI-based platforms enable accurate target identification, lead screening, and toxicity prediction at early stages. This reduces reliance on trial-and-error laboratory methods and minimizes late-stage failures. Their scalability, speed, and ability to support precision medicine make in silico and AI-based technologies essential tools for pharmaceutical and biotechnology companies, driving strong adoption across the market.

The oncology segment holds the largest share of the market.

The oncology segment accounts for the largest share of the Drug Discovery Technologies Market. This growth is driven by the increasing prevalence of cancer worldwide and the rising focus on developing targeted and personalized therapies. Advanced screening platforms, high-throughput assays, and cell-based models are widely used to identify potential drug candidates, validate targets, and optimize leads. Strong investments in cancer research, expanding clinical pipelines, and growing collaboration between pharmaceutical companies and research institutes further support the adoption of these technologies. Improved drug development efficiency and the demand for more effective cancer treatments continue to drive growth in this segment globally.

The US is expected to grow at the highest CAGR during the forecast period.

The US is experiencing the highest growth in the drug discovery technologies market due to several factors. A strong presence of leading pharmaceutical and biotech companies, advanced research infrastructure, and a large number of ongoing oncology programs are key drivers. Increasing adoption of high-throughput screening, 3D cell models, and organ-on-a-chip platforms in cancer research is fueling demand. Supportive regulations, substantial public and private funding for biomedical research, and a focus on precision medicine further contribute to market expansion. Widespread use of advanced discovery technologies and robust collaborations between industry and research institutes enhance innovation, ensuring high-quality outputs and reinforcing North America's leading position globally.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side - 70% and Demand Side- 30%
• By Designation: Managers - 45%, CXOs and Directors - 30%, and Executives - 25%
• By Region: North America - 40%, Europe - 25%, Asia Pacific - 25%, Latin America - 5%, the Middle East & Africa - 5%

Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Illumina, Inc. (US), Revvity (US), F. Hoffmann-La Roche Ltd (Switzerland), Bruker (US), QIAGEN (Germany), Bio-Rad Laboratories, Inc. (US), Tecan Trading AG (Switzerland), Takara Bio Inc. (Japan), Corning Incorporated (US), Hamilton Company (US), PacBio (US), Oxford Nanopore Technologies plc (UK), Promega Corporation (US), Waters Corporation (US), Merck KGAA (Germany), Sartorius AG (Germany), BD (US), Eppendorf SE (Germany), Shimadzu Corporation (Japan), Aurora Biomed Inc. (Canada), Standard BioTools (US), Jeol Ltd. (Japan), Gilson Incorporated (US), BIOMERIEUX (France), Greiner AG (Austria), BGI Group (China), Porvair (UK), Polaris Genomics (US), BICO (Sweden), Creative Bioarray (US), Sphere Bio (UK), GenScript (UK), Schrodinger, Inc. (US), LECO Corporation (US), TransGen Biotech Co., Ltd. (China), BMG LABTECH (Germany), NanoTemper Technologies (Germany), MGI Tech Co., Ltd. (China), Araceli Biosciences (US), Sphere Bio (US), BioSolvelT GmbH (Germany), and Evosep (Denmark) are some of the key companies offering drug discovery technologies products.

Research Coverage

This research report categorizes the drug discovery technologies market by product (reagents & consumables, instruments, bioinformatics tools & software), technology (high-throughput screening technologies, next-generation sequencing, polymerase chain reaction, in-silico/AI-based drug discovery technologies, X-ray crystallography, chromatography, mass spectrometry, other technologies), process (target identification, target validation, hit-to-lead identification, lead optimization, candidate validation), therapeutic area (oncology, infectious diseases, cardiovascular diseases, neurological diseases, endocrine & metabolic diseases, autoimmune disorders, other therapeutic areas), end user (pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations (CROs), other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, And Africa).

The report's scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the drug discovery technologies market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the drug discovery technologies market. This report also includes a competitive analysis of emerging startups in the drug discovery technologies industry ecosystem.

Key Benefits of Buying the Report

The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (increasing adoption of advanced screening platforms, shift toward biologics and advanced therapeutic modalities, transition from conventional two-dimensional cultures to three-dimension models, technological innovations in assay miniaturization and automation), restraints (high up-front investment in instruments, automation, and data infrastructure and shortage of skilled personnel), opportunities (growing demand for in-silico based discovery and increasing need for specialized ADME/Toxicology testing), and challenges (assay reproducibility and standardization issues) influencing the market growth
• Product Development/Innovation: Detailed insights into newly launched products and technological assessment of the drug discovery technologies market
• Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the drug discovery technologies market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Illumina, Inc. (US), Revvity (US), among others, offering products for the drug discovery technologies market. Other companies include Polaris Genomics (US), BICO (Sweden), Creative Bioarray (US), Sphere Bio (UK), GenScript (UK), Schrodinger, Inc. (US), LECO Corporation (US), among others, for the drug discovery technologies market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONS COVERED
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS IN DRUG DISCOVERY TECHNOLOGIES MARKET
• 2.4 HIGH-GROWTH SEGMENTS
• 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT
• 3.2 DRUG DISCOVERY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 3.3 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2025 VS. 2030 (%)

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Increasing adoption of advanced screening platforms
    • 4.2.1.2 Shift toward biologics and advanced therapeutic modalities
    • 4.2.1.3 Transition from conventional two-dimensional cultures to three-dimensional models
    • 4.2.1.4 Technological innovations in assay miniaturization and automation
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 High up-front investment in instruments, automation, and data infrastructure
    • 4.2.2.2 Shortage of skilled personnel
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Growing demand for in-silico-based discovery
    • 4.2.3.2 Increasing need for specialized ADME/Toxicology testing
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Assay reproducibility and standardization issues
• 4.3 UNMET NEEDS AND WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 THREAT OF SUBSTITUTES
  • 5.1.5 THREAT OF NEW ENTRANTS
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
  • 5.2.3 R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY
  • 5.2.4 R&D TRENDS IN GLOBAL PHARMA INDUSTRY
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE OF END USERS, BY KEY PLAYER, 2024
  • 5.5.2 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024
    • 5.5.2.1 Average selling price of instruments, by key player, 2024
    • 5.5.2.2 Average selling price of consumables, by key player, 2024
  • 5.5.3 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY, 2022-2024
  • 5.5.4 AVERAGE SELLING PRICE TREND, BY REGION, 2022-2024
• 5.6 TRADE ANALYSIS
  • 5.6.1 IMPORT SCENARIO FOR HS CODE 3822.00
  • 5.6.2 EXPORT SCENARIO FOR HS CODE 3822.00
  • 5.6.3 IMPORT SCENARIO FOR HS CODE 9027.00
  • 5.6.4 EXPORT SCENARIO FOR HS CODE 9027.00
• 5.7 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.9 INVESTMENT AND FUNDING SCENARIO
• 5.10 CASE STUDY ANALYSIS
  • 5.10.1 AI-DESIGNED IPF DRUG CANDIDATE ADVANCES IN CLINICAL DEVELOPMENT
  • 5.10.2 INDUSTRY CONSORTIUM POOLS DATA TO IMPROVE AI-DRIVEN SMALL MOLECULE DISCOVERY
  • 5.10.3 NEW AI FRAMEWORK FROM IIT MADRAS AND OHIO STATE STREAMLINES MOLECULAR DESIGN
• 5.11 IMPACT OF 2025 US TARIFF ON DRUG DISCOVERY TECHNOLOGIES MARKET
  • 5.11.1 INTRODUCTION
  • 5.11.2 KEY TARIFF RATES
  • 5.11.3 PRICE IMPACT ANALYSIS
  • 5.11.4 KEY IMPACT ON COUNTRIES/REGIONS
    • 5.11.4.1 US
    • 5.11.4.2 Europe
    • 5.11.4.3 Asia Pacific
  • 5.11.5 END-USE INDUSTRY IMPACT
    • 5.11.5.1 Pharmaceutical and Biotechnology Companies
    • 5.11.5.2 Academic and Research Institutes
    • 5.11.5.3 Contract Research Organizations (CROs)

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 KEY EMERGING TECHNOLOGIES
  • 6.1.1 HIGH-THROUGHPUT SCREENING (HTS) & AUTOMATION
  • 6.1.2 AUTOMATED LIQUID HANDLING
• 6.2 ADJACENT TECHNOLOGIES
  • 6.2.1 AI/ML-ENABLED & IN SILICO DISCOVERY PLATFORMS
  • 6.2.2 DISCOVERY INFORMATICS & LAB DIGITALIZATION
• 6.3 TECHNOLOGY/PRODUCT ROADMAP
• 6.4 PATENT ANALYSIS
  • 6.4.1 METHODOLOGY
  • 6.4.2 NUMBER OF PATENTS FILED
  • 6.4.3 LIST OF KEY PATENTS
• 6.5 FUTURE APPLICATIONS
• 6.6 IMPACT OF AI/GEN AI ON DRUG DISCOVERY TECHNOLOGIES MARKET
  • 6.6.1 TOP USE CASES AND MARKET POTENTIAL
  • 6.6.2 BEST PRACTICES IN AI-ENABLED DRUG DISCOVERY WORKFLOWS
  • 6.6.3 CASE STUDIES OF AI IMPLEMENTATION IN DRUG DISCOVERY TECHNOLOGIES MARKET
  • 6.6.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
  • 6.6.5 CLIENTS' READINESS TO ADOPT GENERATIVE MOLECULAR DESIGN IN DRUG DISCOVERY TECHNOLOGIES MARKET

7 SUSTAINABILITY AND REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 INDUSTRY STANDARDS
    • 7.1.2.1 North America
      • 7.1.2.1.1 US
      • 7.1.2.1.2 Canada
    • 7.1.2.2 Europe
      • 7.1.2.2.1 UK
    • 7.1.2.3 Asia Pacific
      • 7.1.2.3.1 China
      • 7.1.2.3.2 Japan
      • 7.1.2.3.3 India
      • 7.1.2.3.4 South Korea
      • 7.1.2.3.5 Australia
      • 7.1.2.3.6 Rest of Asia Pacific
• 7.2 SUSTAINABILITY INITIATIVES
• 7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
• 7.4 CERTIFICATIONS, LABELING, ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOUR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA, BY END USER
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

9 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT

• 9.1 INTRODUCTION
• 9.2 REAGENTS & CONSUMABLES
  • 9.2.1 INNOVATIONS IN ASSAY CHEMISTRY AND SUPPLY CHAIN RESILIENCE TO PROMOTE GROWTH
• 9.3 INSTRUMENTS
  • 9.3.1 HIGH-PERFORMANCE ANALYTICAL ATTRIBUTES AND AUTOMATION TO DRIVE MARKET
• 9.4 BIOINFORMATICS TOOLS & SOFTWARE
  • 9.4.1 AI RISING ADOPTION OF AI AND MACHINE LEARNING FOR PREDICTIVE MODELING TO FUEL MARKET

10 DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY

• 10.1 INTRODUCTION
• 10.2 HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES
  • 10.2.1 AUTOMATED LIQUID HANDLING
    • 10.2.1.1 Increasing focus on precision, integration, and productivity to drive market
  • 10.2.2 MICROPLATE-BASED HTS
    • 10.2.2.1 Rising investments in pharmaceutical and biotechnology R&D to fuel market
  • 10.2.3 LAB-ON-A CHIP
    • 10.2.3.1 Increasing demand for more predictive preclinical models to boost market
  • 10.2.4 LABEL-FREE TECHNOLOGY
    • 10.2.4.1 Real-time, label-free interaction to accelerate segment growth
• 10.3 NEXT-GENERATION SEQUENCING
  • 10.3.1 EXPANDED INTEGRATION OF ADVANCED NGS TECHNOLOGIES TO DRIVE MARKET
• 10.4 POLYMERASE CHAIN REACTION
  • 10.4.1 ENHANCED POLYMERASE CHAIN REACTION INNOVATION AND AUTOMATION TO DRIVE MARKET
• 10.5 IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES
  • 10.5.1 COMPUTATIONAL INTELLIGENCE AND COLLABORATIVE AI INNOVATIONS TO PROPEL MARKET
• 10.6 X-RAY CRYSTALLOGRAPHY
  • 10.6.1 ADVANCED INSTRUMENTATION AND INNOVATIVE X-RAY TECHNIQUES TO BOOST MARKET
• 10.7 CHROMATOGRAPHY
  • 10.7.1 REGULATORY PRESSURES AND COMPLEX BIOLOGICS R&D TO AID GROWTH
• 10.8 MASS SPECTROMETRY
  • 10.8.1 INVESTMENT IN ADVANCED INSTRUMENTATION AND DATA-DRIVEN WORKFLOWS TO DRIVE MARKET
• 10.9 OTHER TECHNOLOGIES

11 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS

• 11.1 INTRODUCTION
• 11.2 TARGET IDENTIFICATION
  • 11.2.1 INCREASING CLINICAL DATA VOLUME TO BOOST MARKET
• 11.3 TARGET VALIDATION
  • 11.3.1 INCREASING TECHNOLOGICAL ADVANCEMENTS TO PROMOTE GROWTH
• 11.4 HIT-TO-LEAD IDENTIFICATION
  • 11.4.1 GROWING ADOPTION OF MULTI-DISCIPLINARY APPROACHES TO DRIVE MARKET
• 11.5 LEAD OPTIMIZATION
  • 11.5.1 INCREASING FOCUS ON REDUCING LATE-STAGE ATTRITION AND INCREASING PROBABILITY OF THERAPEUTIC SUCCESS TO FUEL MARKET
• 11.6 CANDIDATE VALIDATION
  • 11.6.1 INCREASING COMPLEXITY OF THERAPEUTIC MODALITIES TO SUSTAIN GROWTH

12 DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA

• 12.1 INTRODUCTION
• 12.2 ONCOLOGY
  • 12.2.1 SHIFT TOWARD PRECISION ONCOLOGY TO PROMOTE GROWTH
• 12.3 INFECTIOUS DISEASES
  • 12.3.1 RISING ANTIMICROBIAL RESISTANCE AND AI-DRIVEN INNOVATIONS TO DRIVE MARKET
• 12.4 CARDIOVASCULAR DISEASES
  • 12.4.1 INCREASING PREVALENCE OF CARDIOVASCULAR RISK FACTORS TO BOOST MARKET
• 12.5 NEUROLOGICAL DISEASES
  • 12.5.1 INTEGRATION OF ADVANCED MODELS AND STRATEGIC INVESTMENTS TO FUEL MARKET
• 12.6 ENDOCRINE & METABOLIC DISORDERS
  • 12.6.1 RISING PREVALENCE OF TYPE 2 DIABETES, OBESITY, AND ASSOCIATED METABOLIC SYNDROMES TO DRIVE MARKET
• 12.7 AUTOIMMUNE DISORDERS
  • 12.7.1 WIDESPREAD ADOPTION OF BIOLOGICS AND SMALL MOLECULES TO PROPEL MARKET
• 12.8 OTHER THERAPEUTIC AREAS

13 DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER

• 13.1 INTRODUCTION
• 13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 13.2.1 TECHNOLOGY INTEGRATION AND STRATEGIC PARTNERSHIPS TO CONTRBUTE TO GROWTH
• 13.3 ACADEMIC & RESEARCH INSTITUTES
  • 13.3.1 RISING PUBLIC AND PRIVATE RESEARCH FUNDING AND STRONGER ACADEMIC-INDUSTRY COLLABORATION FRAMEWORKS TO AUGMENT GROWTH
• 13.4 CONTRACT RESEARCH ORGANIZATIONS (CROS)
  • 13.4.1 INCREASING R&D OUTSOURCING TO EXPEDITE GROWTH

14 DRUG DISCOVERY TECHNOLOGIES MARKET, BY REGION

• 14.1 INTRODUCTION
• 14.2 NORTH AMERICA
  • 14.2.1 US
    • 14.2.1.1 Expanding network of cross-border partnerships and investments to expedite growth
  • 14.2.2 CANADA
    • 14.2.2.1 Increasing adoption of AI and open-science models to accelerate growth
• 14.3 EUROPE
  • 14.3.1 GERMANY
    • 14.3.1.1 Strong network of publicly funded research institutes, contract research organizations, and pharmaceutical developers to boost market
  • 14.3.2 UK
    • 14.3.2.1 Increasing focus on next-generation computational platforms to promote growth
  • 14.3.3 FRANCE
    • 14.3.3.1 Robust innovation ecosystem and AI-enabled research to propel market
  • 14.3.4 ITALY
    • 14.3.4.1 Rising research funding to contribute to growth
  • 14.3.5 SPAIN
    • 14.3.5.1 Well-established network of research centers and universities to boost market
  • 14.3.6 REST OF EUROPE
• 14.4 ASIA PACIFIC
  • 14.4.1 CHINA
    • 14.4.1.1 Global partnerships to propel market
  • 14.4.2 JAPAN
    • 14.4.2.1 Rising integration of AI and international partnerships to favor growth
  • 14.4.3 INDIA
    • 14.4.3.1 Domestic infrastructure enhancements and government initiatives to support growth
  • 14.4.4 AUSTRALIA
    • 14.4.4.1 Rising adoption of artificial intelligence and advanced computational tools to foster growth
  • 14.4.5 SOUTH KOREA
    • 14.4.5.1 Favorable public policies to support growth
  • 14.4.6 REST OF ASIA PACIFIC
• 14.5 LATIN AMERICA
  • 14.5.1 BRAZIL
    • 14.5.1.1 Public-private collaborations to bolster growth
  • 14.5.2 MEXICO
    • 14.5.2.1 Rising demand for AI-powered research to support growth
  • 14.5.3 REST OF LATIN AMERICA
• 14.6 MIDDLE EAST
  • 14.6.1 GCC COUNTRIES
    • 14.6.1.1 Saudi Arabia
      • 14.6.1.1.1 Increasing focus on regulatory reform, research funding, and international partnerships to boost market
    • 14.6.1.2 UAE
      • 14.6.1.2.1 Strong government vision and cross-sector partnerships to aid growth
    • 14.6.1.3 Rest of GCC countries
  • 14.6.2 REST OF MIDDLE EAST
• 14.7 AFRICA
  • 14.7.1 STRATEGIC PARTNERSHIPS AND CAPACITY BUILDING INITIATIVES TO PROPEL MARKET

15 COMPETITIVE LANDSCAPE

• 15.1 OVERVIEW
• 15.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN
• 15.3 REVENUE ANALYSIS
• 15.4 MARKET SHARE ANALYSIS
• 15.5 BRAND/PRODUCT COMPARISON
  • 15.5.1 THERMO FISHER SCIENTIFIC INC.
  • 15.5.2 MERCK KGAA
  • 15.5.3 AGILENT TECHNOLOGIES, INC.
  • 15.5.4 REVVITY
  • 15.5.5 ILLUMINA, INC.
• 15.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 15.6.1 STARS
  • 15.6.2 EMERGING LEADERS
  • 15.6.3 PERVASIVE PLAYERS
  • 15.6.4 PARTICIPANTS
  • 15.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 15.6.5.1 Company footprint
    • 15.6.5.2 Region footprint
    • 15.6.5.3 Product footprint
    • 15.6.5.4 Technology footprint
    • 15.6.5.5 Process footprint
• 15.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 15.7.1 PROGRESSIVE COMPANIES
  • 15.7.2 RESPONSIVE COMPANIES
  • 15.7.3 DYNAMIC COMPANIES
  • 15.7.4 STARTING BLOCKS
  • 15.7.5 COMPETITIVE BENCHMARKING
    • 15.7.5.1 Detailed list of key startups/SMEs
    • 15.7.5.2 Competitive benchmarking of key startups/SMEs
• 15.8 COMPANY VALUATION AND FINANCIAL METRICS
• 15.9 COMPETITIVE SCENARIO
  • 15.9.1 PRODUCT LAUNCHES
  • 15.9.2 DEALS
  • 15.9.3 EXPANSIONS
  • 15.9.4 OTHER DEVELOPMENTS

16 COMPANY PROFILES

• 16.1 KEY PLAYERS
  • 16.1.1 THERMO FISHER SCIENTIFIC INC.
    • 16.1.1.1 Business overview
    • 16.1.1.2 Products offered
    • 16.1.1.3 Recent developments
      • 16.1.1.3.1 Product launches
      • 16.1.1.3.2 Deals
      • 16.1.1.3.3 Expansions
    • 16.1.1.4 MnM view
      • 16.1.1.4.1 Key strengths/Right to win
      • 16.1.1.4.2 Strategic choices
      • 16.1.1.4.3 Weaknesses/Competitive threats
  • 16.1.2 MERCK KGAA
    • 16.1.2.1 Business overview
    • 16.1.2.2 Products offered
    • 16.1.2.3 Recent developments
      • 16.1.2.3.1 Deals
      • 16.1.2.3.2 Expansions
    • 16.1.2.4 MnM view
      • 16.1.2.4.1 Key strengths/Right to win
      • 16.1.2.4.2 Strategic choices
      • 16.1.2.4.3 Weaknesses/Competitive threats
  • 16.1.3 AGILENT TECHNOLOGIES, INC.
    • 16.1.3.1 Business overview
    • 16.1.3.2 Products offered
    • 16.1.3.3 Recent developments
      • 16.1.3.3.1 Product launches
      • 16.1.3.3.2 Expansions
    • 16.1.3.4 MnM view
      • 16.1.3.4.1 Key strengths/Right to win
      • 16.1.3.4.2 Strategic choices
      • 16.1.3.4.3 Weaknesses/Competitive threats
  • 16.1.4 REVVITY
    • 16.1.4.1 Business overview
    • 16.1.4.2 Products offered
    • 16.1.4.3 Recent developments
      • 16.1.4.3.1 Product launches
      • 16.1.4.3.2 Deals
      • 16.1.4.3.3 Expansions
    • 16.1.4.4 MnM view
      • 16.1.4.4.1 Key strengths/Right to win
      • 16.1.4.4.2 Strategic choices
      • 16.1.4.4.3 Weaknesses/Competitive threats
  • 16.1.5 ILLUMINA, INC.
    • 16.1.5.1 Business overview
    • 16.1.5.2 Products offered
    • 16.1.5.3 Recent developments
      • 16.1.5.3.1 Product launches
      • 16.1.5.3.2 Deals
      • 16.1.5.3.3 Expansions
      • 16.1.5.3.4 Other developments
    • 16.1.5.4 MnM view
      • 16.1.5.4.1 Key strengths/Right to win
      • 16.1.5.4.2 Strategic choices
      • 16.1.5.4.3 Weaknesses/Competitive threats
  • 16.1.6 DANAHER CORPORATION
    • 16.1.6.1 Business overview
    • 16.1.6.2 Products offered
    • 16.1.6.3 Recent developments
      • 16.1.6.3.1 Product launches
      • 16.1.6.3.2 Deals
      • 16.1.6.3.3 Expansions
    • 16.1.6.4 MnM view
      • 16.1.6.4.1 Key strengths/Right to win
      • 16.1.6.4.2 Strategic choices
      • 16.1.6.4.3 Weaknesses/Competitive threats
  • 16.1.7 F. HOFFMANN-LA ROCHE LTD
    • 16.1.7.1 Business overview
    • 16.1.7.2 Products offered
    • 16.1.7.3 Recent developments
      • 16.1.7.3.1 Product launches
      • 16.1.7.3.2 Deals
      • 16.1.7.3.3 Other developments
  • 16.1.8 BRUKER
    • 16.1.8.1 Business overview
    • 16.1.8.2 Products offered
    • 16.1.8.3 Recent developments
      • 16.1.8.3.1 Product launches
      • 16.1.8.3.2 Deals
      • 16.1.8.3.3 Expansions
  • 16.1.9 QIAGEN
    • 16.1.9.1 Business overview
    • 16.1.9.2 Products offered
    • 16.1.9.3 Recent developments
      • 16.1.9.3.1 Product launches
      • 16.1.9.3.2 Deals
      • 16.1.9.3.3 Expansions
  • 16.1.10 BIO-RAD LABORATORIES, INC.
    • 16.1.10.1 Business overview
    • 16.1.10.2 Products offered
    • 16.1.10.3 Recent developments
      • 16.1.10.3.1 Product launches
      • 16.1.10.3.2 Deals
  • 16.1.11 TECAN TRADING AG
    • 16.1.11.1 Business overview
    • 16.1.11.2 Products offered
  • 16.1.12 TAKARA BIO INC.
    • 16.1.12.1 Business overview
    • 16.1.12.2 Products offered
    • 16.1.12.3 Recent developments
      • 16.1.12.3.1 Product launches
  • 16.1.13 CORNING INCORPORATED
    • 16.1.13.1 Business overview
    • 16.1.13.2 Products offered
  • 16.1.14 HAMILTON COMPANY
    • 16.1.14.1 Business overview
    • 16.1.14.2 Products offered
    • 16.1.14.3 Recent developments
      • 16.1.14.3.1 Product launches
      • 16.1.14.3.2 Deals
  • 16.1.15 PACBIO
    • 16.1.15.1 Business overview
    • 16.1.15.2 Products offered
    • 16.1.15.3 Recent developments
      • 16.1.15.3.1 Product launches
      • 16.1.15.3.2 Expansions
  • 16.1.16 OXFORD NANOPORE TECHNOLOGIES PLC
    • 16.1.16.1 Business overview
    • 16.1.16.2 Products offered
    • 16.1.16.3 Recent developments
      • 16.1.16.3.1 Product launches
      • 16.1.16.3.2 Deals
  • 16.1.17 PROMEGA CORPORATION
    • 16.1.17.1 Business overview
    • 16.1.17.2 Products offered
  • 16.1.18 WATERS CORPORATION
    • 16.1.18.1 Business overview
    • 16.1.18.2 Products offered
    • 16.1.18.3 Recent developments
      • 16.1.18.3.1 Product launches
      • 16.1.18.3.2 Deals
  • 16.1.19 SARTORIUS AG
    • 16.1.19.1 Business overview
    • 16.1.19.2 Products offered
    • 16.1.19.3 Recent developments
      • 16.1.19.3.1 Deals
  • 16.1.20 BD
    • 16.1.20.1 Business overview
    • 16.1.20.2 Products offered
    • 16.1.20.3 Recent developments
      • 16.1.20.3.1 Product launches
      • 16.1.20.3.2 Deals
  • 16.1.21 EPPENDORF SE
    • 16.1.21.1 Business overview
    • 16.1.21.2 Products offered
    • 16.1.21.3 Recent developments
      • 16.1.21.3.1 Deals
  • 16.1.22 SHIMADZU CORPORATION
    • 16.1.22.1 Business overview
    • 16.1.22.2 Business overview
    • 16.1.22.3 Products offered
  • 16.1.23 AURORA BIOMED INC.
    • 16.1.23.1 Business overview
    • 16.1.23.2 Products offered
  • 16.1.24 STANDARD BIOTOOLS
    • 16.1.24.1 Business overview
    • 16.1.24.2 Products offered
  • 16.1.25 JEOL LTD.
    • 16.1.25.1 Business overview
    • 16.1.25.2 Products offered
  • 16.1.26 GILSON INCORPORATED
    • 16.1.26.1 Business overview
    • 16.1.26.2 Products offered
  • 16.1.27 BIOMERIEUX
    • 16.1.27.1 Business overview
    • 16.1.27.2 Products offered
  • 16.1.28 GREINER AG
    • 16.1.28.1 Business overview
    • 16.1.28.2 Products offered
  • 16.1.29 BGI GROUP
    • 16.1.29.1 Business overview
    • 16.1.29.2 Products offered
  • 16.1.30 PORVAIR
    • 16.1.30.1 Business overview
    • 16.1.30.2 Products offered
• 16.2 OTHER PLAYERS
  • 16.2.1 POLARIS GENOMICS
  • 16.2.2 BICO
  • 16.2.3 CREATIVE BIOARRAY
  • 16.2.4 SPHERE BIO
  • 16.2.5 GENSCRIPT
  • 16.2.6 SCHRODINGER, INC.
  • 16.2.7 LECO CORPORATION
  • 16.2.8 TRANSGEN BIOTECH CO., LTD
  • 16.2.9 BMG LABTECH
  • 16.2.10 NANOTEMPER TECHNOLOGIES
  • 16.2.11 MGI TECH CO., LTD.
  • 16.2.12 ARACELI BIOSCIENCES
  • 16.2.13 ANALYTIK JENA GMBH+CO. KG
  • 16.2.14 BIOSOLVEIT GMBH
  • 16.2.15 EVOSEP

17 RESEARCH METHODOLOGY

• 17.1 RESEARCH DATA
  • 17.1.1 SECONDARY DATA
    • 17.1.1.1 Key data from secondary sources
  • 17.1.2 PRIMARY DATA
    • 17.1.2.1 Key data from primary sources
    • 17.1.2.2 Key primary participants
    • 17.1.2.3 Breakdown of primary interviews
    • 17.1.2.4 Key industry insights
• 17.2 MARKET SIZE ESTIMATION
  • 17.2.1 BOTTOM-UP APPROACH
  • 17.2.2 TOP-DOWN APPROACH
  • 17.2.3 BASE NUMBER CALCULATION
• 17.3 GROWTH FORECAST MODEL
• 17.4 DATA TRIANGULATION
• 17.5 FACTOR ANALYSIS
• 17.6 RESEARCH ASSUMPTIONS
• 17.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT

18 APPENDIX

• 18.1 DISCUSSION GUIDE
• 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 18.3 CUSTOMIZATION OPTIONS
• 18.4 RELATED REPORTS
• 18.5 AUTHOR DETAILS